GlycoMimetics Inc’s recently made public that its Chief Medical Officer Rock Edwin acquired Company’s shares for reported $30716.0 on Jun 21 ’24. In the deal valued at $0.27 per share,115,000 shares were bought. As a result of this transaction, Rock Edwin now holds 680,403 shares worth roughly $0.18 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Rock Edwin bought 190,000 shares, generating $48,108 in total proceeds. Upon buying the shares at $0.25, the Chief Medical Officer now owns 565,403 shares.
Before that, Hahn Brian M. bought 17,500 shares. GlycoMimetics Inc shares valued at $4,335 were divested by the SVP Finance, CFO at a price of $0.25 per share. As a result of the transaction, Hahn Brian M. now holds 70,643 shares, worth roughly $19073.61.
CapitalOne initiated its GlycoMimetics Inc [GLYC] rating to an Overweight in a research note published on December 22, 2023; the price target was $12. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in mid November from “a Hold” to “a Buy”. ROTH Capital began covering GLYC with “Buy” recommendation on November 14, 2019. SunTrust revised its rating on August 05, 2019. It rated GLYC as “a Hold” which previously was an “a Buy”.
Price Performance Review of GLYC
On Monday, GlycoMimetics Inc [NASDAQ:GLYC] saw its stock jump 3.61% to $0.27. Over the last five days, the stock has gained 1.37%. GlycoMimetics Inc shares have fallen nearly -88.70% since the year began. Nevertheless, the stocks have fallen -85.89% over the past one year. While a 52-week high of $3.53 was reached on 01/23/24, a 52-week low of $0.23 was recorded on 06/20/24. SMA at 50 days reached $0.7959, while 200 days put it at $1.8447. A total of 6.6 million shares were traded, compared to the trading of 0.91 million shares in the previous session.
Levels Of Support And Resistance For GLYC Stock
The 24-hour chart illustrates a support level at 0.2599, which if violated will result in even more drops to 0.2532. On the upside, there is a resistance level at 0.2734. A further resistance level may holdings at 0.2802. The Relative Strength Index (RSI) on the 14-day chart is 29.38, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0033, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.38%. Stochastics %K at 35.33% indicates the stock is a holding.
#####
#####
#####
#####
